Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy
Roswitha Runge1, Anne Naumann1, Matthias Miederer1,2
1Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany.
Abstract:
Possibilities to improve the therapeutic efficacy of Lu-177-PSMA-617 radionuclide therapy by modulation of target expression are being investigated. Knowledge on regulatory factors that promote prostate cancer (PCa) progression may contribute to targeting prostate cancer more effectively. We aimed at the stimulation of PCa cell lines using the substances 5-aza-2'-deoxycitidine (5-aza-dC) and valproic acid (VPA) to achieve increased prostate-specific membrane antigen (PSMA) expression. PC3, PC3-PSMA, and LNCaP cells were incubated with varying concentrations of 5-aza-dC and VPA to investigate the cell-bound activity of Lu-177-PSMA-617. Stimulation effects on both the genetically modified cell line PC3-PSMA and the endogenously PSMA-expressing LNCaP cells were demonstrated by increased cellular uptake of the radioligand. For PC3-PSMA cells, the fraction of cell-bound radioactivity was enhanced by about 20-fold compared to that of the unstimulated cells. Our study reveals an increased radioligand uptake mediated by stimulation for both PC3-PSMA and LNCaP cell lines. In perspective of an enhanced PSMA expression, the present study might contribute to advanced radionuclide therapy approaches that improve the therapeutic efficacy, as well as combined treatment options.
Insights
Investigating prostate cancer (PCa) treatments, this study used 5-aza-2'-deoxycitidine and valproic acid to increase prostate-specific membrane antigen (PSMA) expression. This enhanced the uptake of Lu-177-PSMA-617, improving potential radionuclide therapy efficacy.
Area of Science:
- Oncology
- Nuclear Medicine
- Molecular Biology
Background:
- Improving Lu-177-PSMA-617 radionuclide therapy efficacy is crucial for prostate cancer (PCa) treatment.
- Understanding PCa progression factors can enhance targeted therapies.
- Modulating target expression offers a potential strategy to boost therapeutic outcomes.
Purpose of the Study:
- To investigate the stimulation of prostate cancer cell lines to increase prostate-specific membrane antigen (PSMA) expression.
- To evaluate the impact of 5-aza-2 -deoxycitidine (5-aza-dC) and valproic acid (VPA) on PSMA expression.
- To assess the effect of enhanced PSMA expression on the cellular uptake of Lu-177-PSMA-617.
Main Methods:
- PC3, PC3-PSMA, and LNCaP prostate cancer cell lines were treated with varying concentrations of 5-aza-dC and VPA.
- Cell-bound radioactivity of Lu-177-PSMA-617 was measured to determine radioligand uptake.
- PSMA expression levels were analyzed in response to the applied substances.
Main Results:
- Both 5-aza-dC and VPA demonstrated stimulatory effects on PSMA expression in PC3-PSMA and LNCaP cells.
- Cellular uptake of the radioligand Lu-177-PSMA-617 significantly increased in stimulated cells.
- PC3-PSMA cells showed approximately a 20-fold enhancement in cell-bound radioactivity compared to unstimulated controls.
Conclusions:
- Stimulation with 5-aza-dC and VPA effectively increases PSMA expression and radioligand uptake in prostate cancer cell lines.
- Enhanced PSMA expression holds promise for improving the efficacy of Lu-177-PSMA-617 radionuclide therapy.
- This approach may pave the way for advanced radionuclide therapies and combination treatment strategies for prostate cancer.
